Elmwood Wealth Management, Inc. Editas Medicine, Inc. Transaction History

Elmwood Wealth Management, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	BUY	$7.03 - $11.53 $112,655 - $184,768	16,025 Added 114.48%	30,023 $217,000
Q4 2022 Jan 25, 2023	SELL	$8.32 - $13.21 $84,256 - $133,777	-10,127 Reduced 41.98%	13,998 $0
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $194,864 - $311,205	-16,025 Reduced 39.91%	24,125 $295,000
Q2 2022 Jul 12, 2022	BUY	$9.99 - $21.35 $1,268 - $2,711	127 Added 0.32%	40,150 $475,000
Q2 2020 Aug 13, 2020	SELL	$18.5 - $34.34 $1.42 Million - $2.64 Million	-76,854 Reduced 65.76%	40,023 $1.18 Million
Q1 2020 May 12, 2020	BUY	$14.88 - $32.78 $1.14 Million - $2.52 Million	76,854 Added 192.02%	116,877 $2.32 Million
Q4 2019 Feb 05, 2020	SELL	$19.49 - $32.63 $75,270 - $126,017	-3,862 Reduced 8.8%	40,023 $1.19 Million
Q3 2019 Nov 13, 2019	SELL	$22.49 - $26.81 $307,798 - $366,921	-13,686 Reduced 23.77%	43,885 $998,000
Q2 2019 Aug 07, 2019	SELL	$20.48 - $27.76 $280,289 - $379,923	-13,686 Reduced 19.21%	57,571 $1.42 Million
Q1 2019 May 22, 2019	SELL	$19.43 - $26.41 $177,279 - $240,964	-9,124 Reduced 11.35%	71,257 $1.74 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $248,948 - $435,077	-13,686 Reduced 14.55%	80,381 $1.83 Million
Q3 2018 Oct 11, 2018	SELL	$27.65 - $38.39 $252,278 - $350,270	-9,124 Reduced 8.84%	94,067 $2.99 Billion
Q2 2018 Aug 22, 2018	SELL	$31.4 - $41.01 $429,740 - $561,262	-13,686 Reduced 11.71%	103,191 $3.7 Billion
Q1 2018 May 10, 2018	BUY	$29.84 - $44.08 $3.49 Million - $5.15 Million	116,877 New	116,877 $3.87 Billion

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Elmwood Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Elmwood Wealth Management, Inc. with notifications on news.